Novavax signs deal with SK Bioscience for 40 mln vaccine doses for S. Korea

U.S. drug developer Novavax Inc said on Monday it has signed a license agreement with South Korea manufacturer SK Bioscience to produce 40 million doses of its COVID-19 vaccine for South Korea. “Concurrently, SK Bioscience has finalized an advance purchase agreement with the Korean government to supply 40 million doses of NVX-CoV2373 to the Republic of Korea beginning in 2021,” Novavax said in a statement https://bit.ly/37eMKB2.